Amicare Sp. z o.o. S.K.

At Amicare Sp. z o.o. S.K. in Lodz, a major focus is digestive system disease research, especially Crohn’s disease and ulcerative colitis. These studies are designed to evaluate new treatment options, compare them with placebo, and better understand how to achieve and maintain remission in people with active inflammatory bowel disease.

• Clinical research in Crohn’s disease and ulcerative colitis
• Studies of symptom control, remission, and endoscopic improvement
• Evaluation of new therapies and treatment effectiveness in active disease

The site is active across both short-term and longer-term investigations, reflecting a strong interest in improving care for patients with difficult-to-treat intestinal inflammation.

Another prominent area is immune system disease research, including rheumatoid arthritis and other immune-driven conditions. These trials aim to test whether new medicines can reduce inflammation, improve disease control, and offer better options for people with newly diagnosed or ongoing immune disorders.

• Rheumatoid arthritis studies focused on reducing inflammatory activity
• Research on immune system regulation and treatment response
• Trials assessing safety, tolerability, and clinical benefit of new therapies

This therapeutic area highlights the site’s involvement in advancing care for chronic conditions where controlling immune activity is central to treatment.

The site also conducts important research in skin and connective tissue diseases, with studies in atopic dermatitis, psoriasis, acne vulgaris, hidradenitis suppurativa, and prurigo nodularis. These trials are generally aimed at testing new therapies, improving symptom relief, and measuring changes in skin disease severity and quality of life.

• Atopic dermatitis and psoriasis treatment research
• Studies in acne vulgaris and hidradenitis suppurativa
• Evaluation of therapies for itch, skin lesions, and inflammatory skin control

Dermatology remains a strong research theme at this site, with multiple trials exploring both disease improvement and long-term treatment performance.

Within its Neurology department, Amicare Sp. z o.o. S.K. participates in studies of generalized myasthenia gravis and tuberous sclerosis complex. These projects are intended to assess whether new therapies can improve neurological symptoms, support long-term disease management, and maintain safety in patients across different age groups.

• Generalized myasthenia gravis research in pediatric and adult populations
• Tuberous sclerosis complex studies focused on seizure-related disease control
• Trials evaluating safety, tolerability, and clinical effectiveness of emerging treatments

These neurology studies show the site’s involvement in complex chronic conditions where sustained symptom control is especially important.

Research in respiratory tract diseases and immune system phenomena includes work on chronic obstructive pulmonary disease, allergic rhinoconjunctivitis, and birch pollen-induced allergic rhinitis. The purpose of these trials is to test new approaches that may reduce symptoms, improve breathing or allergy control, and lessen the burden of seasonal or chronic respiratory disease.

• COPD studies aimed at reducing exacerbations and improving symptom control
• Allergic rhinitis and rhinoconjunctivitis research in children, adolescents, and adults
• Evaluation of therapies for allergy relief and respiratory disease management

This area adds a broad respiratory and allergy component to the site’s clinical trial portfolio.

The trial portfolio at Amicare Sp. z o.o. S.K. also includes studies in other immune-mediated diseases, such as gastroparesis and related digestive conditions, along with investigations of long-term treatment safety and comparative effectiveness. These projects are designed to refine diagnosis, improve ongoing disease control, and support better treatment choices across multiple chronic illnesses.

• Gastroparesis and related digestive motility research
• Long-term safety and tolerability studies across chronic diseases
• Comparative trials helping identify more effective treatment strategies

With 40 trials and 20 investigators, the site shows a broad and active commitment to advancing care in inflammatory, neurological, dermatologic, respiratory, and allergy-related disease areas.